Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gynecologic 1

Conditions

Prostatic Neoplasms 1Pituitary ACTH Hypersecretion 1Peritoneal Neoplasms 1Ovarian Neoplasms 1Ovarian Diseases 1Neoplasms by Site 1Neoplasms 1Hypertension 1Genital Neoplasms, Female 1Fallopian Tube Neoplasms 1Fallopian Tube Diseases 1Endometrial Neoplasms 1Diabetes Mellitus, Type 2 1Cushing Syndrome 1Carcinoma, Pancreatic Ductal 1Adrenocortical Carcinoma 1Adrenal Cortex Neoplasms 1Adenocarcinoma 1ACTH Syndrome, Ectopic 1

Interventions

relacorilant 1nilotinib 1Therapeutic Touch 1Standard of Care 1Radiotherapy 1Practice Guidelines as Topic 1Paclitaxel 1Methods 1Laparoscopy 1Fulvestrant 1Electrocardiography 1Educational Status 1Early Intervention, Educational 1Bevacizumab 1130-nm albumin-bound paclitaxel 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Genital Neoplasms, Female × relacorilant × 90 days × Clear all
NCT06906341 2026-04-14

Relacorilant in Combination With Different Treatment Regimens in Patients With Gynecological Cancers

Corcept Therapeutics

Phase 2 Recruiting
270 enrolled
Gynecologic

Fallopian Tube Diseases, Fallopian Tube Neoplasms, Genital Neoplasms, Female, Neoplasms, Neoplasms by Site, Ovarian Diseases, Ovarian Neoplasms, Peritoneal Neoplasms, Endometrial Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡